What one share of Ultragenyx Pharmaceutical holds
We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Ultragenyx Pharmaceutical’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $7.13 |
|---|---|
| Profit | −$5.83 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$4.86 |
| Cash and investments | $1.27 |
| Book value | −$2.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | — | −$14.20 | $0.79 | −$9.87 | — | — |
| 2013 | — | −$14.87 | $0.12 | −$9.34 | — | −$19.87 |
| 2014 | — | −$2.25 | $0.07 | −$1.63 | $0.00 | $5.79 |
| 2015 | — | −$3.96 | $0.13 | −$3.02 | $0.00 | $13.66 |
| 2016 | $0.00 | −$6.21 | $0.26 | −$4.32 | — | $11.49 |
| 2017 | $0.06 | −$7.12 | $0.07 | −$6.05 | — | $8.68 |
| 2018 | $1.03 | −$3.97 | $0.08 | −$5.92 | — | $11.97 |
| 2019 | $1.83 | −$7.12 | $0.44 | −$6.54 | — | $11.30 |
| 2020 | $4.45 | −$3.07 | $0.72 | −$2.89 | — | $17.28 |
| 2021 | $5.18 | −$6.70 | $1.08 | −$6.07 | — | $13.30 |
| 2022 | $5.20 | −$10.12 | $1.66 | −$7.10 | — | $5.01 |
| 2023 | $5.90 | −$8.26 | $0.60 | −$7.06 | — | $3.34 |
| 2024 | $6.19 | −$6.29 | $0.08 | −$4.65 | — | $2.76 |
| 2025 | $6.83 | −$5.83 | $0.06 | −$4.79 | — | −$0.83 |
Common questions about Ultragenyx Pharmaceutical
How much does one share of Ultragenyx Pharmaceutical earn?
Over the last 12 months, Ultragenyx Pharmaceutical lost $5.83 for each share on $7.13 of sales.
Does Ultragenyx Pharmaceutical pay a dividend?
Ultragenyx Pharmaceutical didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Ultragenyx Pharmaceutical’s book value per share?
Ultragenyx Pharmaceutical’s book value is negative (−$2.95 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Ultragenyx Pharmaceutical have?
Each share of Ultragenyx Pharmaceutical has $1.27 of cash and investments, as of June 30, 2026.
What is Ultragenyx Pharmaceutical’s free cash flow per share?
−$4.86 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Ultragenyx Pharmaceutical bought back shares?
Ultragenyx Pharmaceutical’s share count rose about 7059% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.